Tirzepatide
A dual GIP and GLP-1 receptor agonist behind Mounjaro and Zepbound — an FDA-approved drug supported by large, high-quality human trials for type 2 diabetes and weight management.
Quick take
- What it is: a dual GIP/GLP-1 receptor agonist — a peptide-based prescription medicine, not a research chemical.
- What it is used for: type 2 diabetes and chronic weight management.
- What we actually know: backed by large randomized controlled trials (the SURPASS and SURMOUNT programs).
- Status: FDA-approved and available by prescription as Mounjaro (diabetes) and Zepbound (weight management).
What it is
Tirzepatide is a dual GIP and GLP-1 receptor agonist — a single engineered peptide that activates two gut-hormone (incretin) receptors at once. It is included here as an important reference point: unlike most peptides covered on this site, tirzepatide is an FDA-approved, prescription drug with a large, high-quality human evidence base.1
It is sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management).
How it works
GLP-1 and GIP are both hormones released after eating. GLP-1 stimulates insulin, suppresses glucagon, slows stomach emptying and reduces appetite; GIP also influences insulin secretion and fat metabolism. Tirzepatide is designed to activate both receptors with a single molecule, and is modified to last long enough for once-weekly injection.1 The combined activity is associated with improved blood-sugar control and substantial appetite and weight effects.
What the evidence shows
Animal studies
Preclinical work in rodents and other models helped establish that dual GIP/GLP-1 activation could improve glucose handling and reduce body weight, supporting progression to human trials.2 For an approved drug like tirzepatide, however, the decisive evidence comes from the human program below.
Human studies
Tirzepatide is supported by large randomized controlled trials. The SURPASS program studied it for type 2 diabetes, and the SURMOUNT program studied it for weight management, with average weight reductions among the largest reported for an incretin-based therapy.3,4 This depth of human evidence is exactly what most peptides marketed online lack.
Dosages reported in the literature
Informational only. Tirzepatide is a prescription medicine. The figures below summarize approved dosing for context; they are not a recommendation. Dosing must be set and supervised by a prescriber.
| Use | Route | Reported / approved range |
|---|---|---|
| Type 2 diabetes (Mounjaro) | Subcutaneous, weekly | Titrated, commonly up to ~15 mg weekly |
| Weight management (Zepbound) | Subcutaneous, weekly | Titrated, commonly up to ~15 mg weekly |
Doses are started low and increased gradually to reduce gastrointestinal side effects.
Safety & side effects
The most common side effects are gastrointestinal — nausea, vomiting, diarrhea and constipation — usually worst when starting or increasing the dose. Labeled warnings include a boxed warning about thyroid C-cell tumors seen in rodents, and cautions around pancreatitis, gallbladder disease and use in certain conditions.1 It is a prescription medicine and is not appropriate for everyone.
Legal & regulatory status
Tirzepatide is FDA-approved and available by prescription as Mounjaro and Zepbound. Note that compounded or “research” tirzepatide sold outside the regulated supply chain does not carry the same quality assurances as the approved products, and such products have been the subject of FDA safety communications.5 Rules differ by country and change over time.
References
- MOUNJARO (tirzepatide) injection, for subcutaneous use. Highlights of Prescribing Information. Eli Lilly and Company; Initial U.S. Approval 2022. U.S. Food and Drug Administration. DailyMed label and FDA Drugs@FDA label PDF. [accessdata.fda.gov]
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. [PMID 30473097, doi:10.1016/j.molmet.2018.09.009]
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. [PMID 34170647, doi:10.1056/NEJMoa2107519]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. [PMID 35658024, doi:10.1056/NEJMoa2206038]
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA Drug Alerts and Statements, 2024-2025 (resolution of tirzepatide shortage; adverse-event reports for compounded tirzepatide). [fda.gov]